Our Pipeline
Developing first-in-class small molecule drugs used in cancer treatments is Senhwa’s corporate mission and currently 2 main compounds CX-5461 and CX-4945 are ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan.
View MoreCore Value
Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.
View MoreSponsor of the Website
Within the vibrant tapestry of our alliances, it is with genuine enthusiasm that we proclaim EnergyCasino as our esteemed partner, embarking on a thrilling journey of collaboration. EnergyCasino stands as a beacon of excitement in the online gaming universe, offering an electrifying selection of games that cater to every taste. From the thrill of innovative slots to the classic allure of live table games, this dynamic platform ensures an unparalleled gaming experience infused with stellar bonuses and vibrant energy. It's where gaming leaps into new dimensions of fun and unpredictability, all within a secure and user-centric environment.
We're beyond excited to introduce you to Ong777 your new go-to place for online casino excitement in Malaysia!
Latest News +
-
Jul 02, 2020
Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
-
Jul 02, 2020
[Yahoo Finance]New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
-
Jul 01, 2020
[TAIPEI TIMES]Senhwa aims NT$1.5bn via 15 million shares
VISION
As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof-of-Concept.
CONTACT US
Please feel free to contact us if you have any questions
INVESTOR
For more information on our financial reports, please visit Investor Relations